Interestingly, the traditional chemotherapeutic agent doxorubicin has been shown to downregulate CIP2A expression, and increased CIP2A expression confers doxorubicin resistance in breast cancer cells [23]. The gene discussed is CIP2A; the disease is breast carcinoma.